Lupin acquires Temmler Pharma

A day after announcing $880 Million acquisition in the US, drug maker Lupin will acquire specialty product portfolio from German company Temmler Pharma for an undisclosed amount. Temmler business has a strong strategic fit with Lupin Hormosan business in Germany and enables Lupin to bring an enhanced specialty CNS portfolio to German market.

Established in 1917, Temmler is a part of Aenova Group, a pharmaceutical contract manufacturer. Hormosan, also a German Pharma company was acquired by Lupin in 2008. Based in Marburg, Germany, Temmler has a specialty portfolio of 13 products including key Central Nervous System products and specialty products that address rare disease areas like Myasthenia Gravis, Huntington disease as well as fast growing dermatology products for anti-wart treatment.

This is Lupin sixth acquisition in last 18 months. In February 2014, Lupin had acquired Netherland based Nanomi for an undisclosed amount. A month later, it acquired control of Mexican company Grin. In May this year, it bought Brazilian company Medquimica Industria Farmaceutica.

Earlier this month, Lupin acquired ZAO Bio Biocom in Russia, again for an undisclosed amount. On Thursday, it announced acquisition of New Jersey based generic drugs firm Gavis for $880 Million. Gavis is the largest overseas acquisition by an Indian pharma company in US.

Lupin acquires US Generic firm Gavis

Mumbai based drug maker Lupin Ltd has entered into a definitive agreement to acquire New Jersey based privately held Gavis Pharmaceuticals Ltd and Novel Laboratories Inc. for $880 Million to expand in the US generic drug market. This is the biggest acquisition in the US by an Indian company. The acquisition is cash free and debt free.

Gavis brings to Lupin a highly skilled US based R&D organization, which would complement Lupin Coral Springs, Florida, inhalation R&D center and a New Jersey based manufacturing facility which will become Lupin first manufacturing site in the US. The acquisition enhances Lupin scale in the US generic market and also broadens its pipeline in dermatology, controlled substance products and other high valued and niche generics.

On 2^nd July, Lupin had acquired Russian company Biocom for an undisclosed amount. The company required sales of 861.2 Million Ruble in fiscal year 2014. In May 2015, Lupin entered into Brazilian pharmaceuticals market by acquiring Medquimica Industrial Pharmaceutical S.A Brazil for an undisclosed amount.

Lupin had strengthened its position in Latin American market last year by acquiring Laboratories Grin SA, the fourth largest pharmaceutical company in Mexico in the eye care segment, with sales of $28 Million in 2013.